Miriam Estébanez

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero et al. · The Lancet Infectious Diseases · 2015 · 131 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero et al. · Journal of Antimicrobial Chemotherapy · 2016 · 62 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study

Francisco Javier Membrillo de Novales, Germán Ramírez‐Olivencia, Miriam Estébanez et al. · Preprints.org · 2020 · 38 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +14

<p>Incidence, Characteristics, Laboratory Findings and Outcomes in Acro-Ischemia in COVID-19 Patients</p>

María Noelia Alonso, Tatiana Mata-Forte, Natalia García-León et al. · Vascular Health and Risk Management · 2020 · 33 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +6

Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study

Francisco Javier Membrillo de Novales, Germán Ramírez‐Olivencia, Miriam Estébanez et al. · Preprints.org · 2020 · 29 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +14